Biohaven Ltd. (BHVN)
Healthcare
Biotechnology
13.50 $
-2.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Biohaven Ltd. (BHVN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.4% of the shares are freely tradable; institutional investors hold 97.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
97.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
11.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
82.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
21.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
151Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HHG PLC | 11.65 | 17,534,612 | +1,145.9 | 03/31/2026 |
| BlackRock Inc | 7.45 | 11,222,407 | +18.8 | 03/31/2026 |
| Suvretta Capital Management, LLC | 6.83 | 10,286,937 | +0.0 | 03/31/2026 |
| Stifel Financial Corp | 6.60 | 9,940,885 | +0.0 | 03/31/2026 |
| State Street Corp | 4.40 | 6,618,803 | +15.8 | 03/31/2026 |
| TCG Crossover Management, LLC | 3.08 | 4,631,317 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 2.92 | 4,395,946 | +52.9 | 12/31/2025 |
| StemPoint Capital LP | 2.12 | 3,188,982 | +0.0 | 03/31/2026 |
| Royalty Pharma Sub-Manager, LLC | 1.95 | 2,936,507 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.83 | 4,255,837 | -0.6 | 05/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.